Covid-19 vaccine developers stand out as global drug stocks tread water in the first quarter.
Rubius shows the first hints of clinical anticancer activity, and is suddenly worth $2.4bn.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
The company’s deal with Dragonfly shows that disappointments have not eliminated interest in cytokine approaches.
With a $3.2bn valuation ahead of its Nasdaq float – and a market cap that is now 50% higher – Legend Biotech enters the IPO record books.
The collapse of Rubius’s first attempt to demonstrate the worth of its red blood cell platform proves that this company should never have gone public.
The first clinical data from Rubius Therapeutics will show whether its lead project, RTX-134, has a future. More importantly, the readout is a test of its entire red…
A big valuation at float is no guarantee of ongoing investor support, as a look at the sector’s biggest IPOs reveals.
Biontech and ADC Therapeutics are both heading towards substantial flotations, but it is hard to find evidence that bigger does better.